Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients.

摘要: The discovery of kinase domain mutations in the epidermal growth factor receptor gene (EGFR) never-smoker patients, associated with an increased sensitivity to tyrosine inhibitors (TKIs) such as gefitinib or erlotinib, has been one most relevant findings ever non-small cell lung carcinomas (NSCLC). Since treatment TKIs furthermore shown a clinical benefit head and neck squamous carcinoma (HNSCC) we hypothesized that these could also be present this neoplasia. Current studies looking for EGFR HNSCC are limited results still controversial. In work, screened tumour DNA obtained from 31 Spanish patients by PCR-single-strand conformational polymorphism analysis. None displayed somatic mutation, previously described NSCLC, but other sequence variations were found 9 patients. Accordingly, activating seem rare event suggesting there is little room administration based on presence mutations. Additional investigations about amplification indicated establish potential relationship between overexpression response anti-EGFR therapies.